Dual-action glaucoma drops now approved in U.S.
- Posted on: Nov 3 2017
The FDA has approved latanoprostene bunod (Vyzulta), a nitric oxide-donating prostaglandin analog, for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Source: AAO
Posted in: AAO
